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Predictors of airway hyperreactivity in house dust mite allergic patients
Abstract
Introduction: Airway hyperresponsiveness (AHR) is a cardinal feature of asthma. Asthma is a heterogenous disorder which 
consists of different phenotypes and endotypes. Mechanisms leading to AHR may differ in different asthma subtypes. Allergy to 
perennial allergens, including house dust mites (HDM) is a major risk factor for asthma development. The aim of this study was 
to determine predictors of AHR in a well-characterized population of HDM-allergic patients. 
Material and methods: In a retrospective analysis 843 patients with HDM-allergic rhinitis with/without asthma were evaluated. 
The following parameters were included in the analysis: serum concentration of total (t)- and Dermatophagoides pteronyssinus 
(Dp)-specific IgE, fractional exhaled nitric oxide concentration (FeNO), lung function tests, bronchial challenge with histamine, 
age sex, and body mass index (BMI). Linear regression analysis was used to determine predictors of AHR. 
Results: In a simple linear regression analysis baseline lung function results expressed as either forced expiratory volume in 
1 s (FEV1) or maximal expiratory flow at 50% of the forced vital capacity (MEF50), FeNO, tIgE, DpIgE, age and BMI affected AHR. 
A multiple regression analysis demonstrated that in the whole group of HDM-allergic patients the most important, independent 
predictors of AHR were MEF50, FeNO and DpIgE. 
Conclusion: Even in a well-characterized asthma phenotype several processes participate in development of AHR. Major, inde-
pendent predictors of AHR: lung function parameters, FeNO and DpIgE indicate possible targets for therapeutic intervention in 
a population of HDM-allergic patients. 
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Introduction
Airway hyperresponsiveness (AHR) is a car-
dinal feature of asthma [1]. However, it is pre-
sent not only in asthma patients but in patients 
with other respiratory illnesses as well [1, 2]. 
Nevertheless, moderately-severe AHR is virtu-
ally pathognomonic for asthma. Although the 
exact mechanism of AHR has not been fully 
elucidated it is known that AHR results from 
a complex interaction between several mecha-
nisms including bronchial inflammation and 
airway remodeling [1–3]. 
Association of AHR with asthma is even more 
complex due to heterogeneity of asthma. Asthma 
is not a homogenous disease but consists of se-
veral phenotypes and endotypes which differ in 
type of airway inflammation, clinical course and 
response to different treatment modalities [4]. The 
heterogeneity of airway inflammation may affect 
assessment of its intensity using conventional, 
noninvasive methods such as evaluation of exha-
led nitric oxide concentration [5]. This in turn 
may interfere with attempts aimed at determining 
the role of individual factors in AHR. Among all 
asthma phenotypes, allergic asthma is the most 
frequently encountered [4]. In a general popula-
tion, allergic patients are more likely to suffer from 
asthma than non-atopic individuals [6]. Moreover, 
greater intensity of atopy seems to be associated 
with greater risk of AHR and asthma [7]. 
Allergic asthma is characterized by eosino-
philic airway inflammation and clinical favorable 
response to anti-immunoglobulin E (anti-IgE) 
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therapy and allergen immunotherapy which 
support the role of aeroallergens and IgE in its 
pathogenesis [8]. In a great majority of allergic 
asthma patients involvement of upper respira-
tory tract, manifested as allergic rhinitis, can 
be demonstrated, while in a substantial part of 
allergic rhinitis patients clinical asthma or AHR 
can be found [6, 9]. Various aeroallergens exhibit 
varying degree of association with asthma and 
AHR with house dust mite (HDM) allergens, inc-
luding Dermatophagoides pteronyssinus (Dp) and 
Dermatophagoides farinae (Df) demonstrating the 
greatest association [10–19].
Sensitization to Dp/Df has been shown in 
the vast majority of allergic asthma patients in 
different countries, different climates and diffe-
rent populations including populations of adults 
and children [10–19]. Moreover, a  relationship 
between sensitization to HDM and AHR and/or 
asthma severity has been demonstrated [13–15]. 
This was clearly shown in a population of young 
adults in whom AHR was more frequent HDM-al-
lergic patients than in those sensitized to other 
allergens [16]. In HDM-allergic patients exposure 
to HDM allergens triggers asthma symptoms and 
a linear relationship between the risk of appearan-
ce of asthmatic symptoms and the concentration 
of the main Dp allergen — Der p 1 in house dust 
has been demonstrated [17]. Moreover, prolonged 
exposure to house dust is associated with more 
severe asthma and seasonal changes in exposure 
to house dust are reflected in changes of the level 
of AHR in patients with HDM-allergic asthma [18, 
19]. These data argue for an important function of 
both exposure and sensitization to HDM allergens 
in the pathogenesis of asthma and AHR.
Therefore it was of interest to determine 
factors affecting AHR in a  large, homogenous 
population of HDM-allergic patients. 
Material and methods
This is a  retrospective analysis of 843 
house dust mite allergic patients (HDM-AP). The 
patients who underwent a routine evaluation in 
the outpatient Allergy Clinic of the University 
Hospital of Bialystok over a period of 11 years. 
All included patients reported rhinitis and/ 
/or asthma symptoms which were triggered by 
exposure to house dust and had positive skin 
prick tests with Dp and Df allergens. Asthma 
diagnosis was established according to the Global 
Initiative for Asthma (GINA) guidelines [20] by an 
allergy/pulmonary specialist. The diagnosis was 
based on a typical medical history, including asth-
ma symptoms triggered by exposure to house dust 
and if possible demonstration of airway obstruction 
with significant improvement after inhalation of 
400 mcg of salbutamol within 1 year prior to the 
study. Patients treated with systemic or inhaled cor-
ticosteroids, allergen immunotherapy or biologics 
were not included in the study. Lung function tests 
with reversibility test, if indicated, were performed 
as a routine evaluation in allergy clinic. 
In addition to routine tests total and Dp spe-
cific IgE (tIgE and DpIgE, respectively), histamine 
bronchial challenge and exhaled nitric oxide 
concentration were evaluated.
Skin testing 
All persons were skin tested using the prick 
methodology with a screening panel of aeroaller-
gens (Allergopharma, Reinbek, Germany) inclu-
ding the following allergen extracts: 1) Dermato-
phagoides pteronyssinus (Dp); 2) Dermatophago-
ides farinae (Df); 2) trees: including birch, alder, 
hazel and a tree mix; 3) grass mix; 4) mugwort; 
5) cat and dog allergens and 6. Alternaria tenuis. 
The reaction was considered positive when the 
longest wheal diameter induced by an individual 
allergen was equal to or greater than that induced 
by histamine control having at least 3 mm. 
Exhaled nitric oxide concentration
Fractional concentration of nitric oxide in the 
expired air (FeNO) was evaluated “on-line” using 
a chemiluminescence analyzer NOATM 280i (Sie-
vers, Boulder, CO, USA). The measurements were 
performed according to ATS recommendations 
as described before [21]. Briefly, each patient 
exhaled against the fixed expiratory resistance of 
16 cm H20, which resulted in a constant flow 
of 50 mL/s. Both NO concentration and flow rate 
were displayed on the screen. A plateau of NO 
concentration in the exhaled air at the selected 
exhalation rate was automatically selected by the 
computer software according to the ATS recom-
mendations. The NO measurements were repeated 
3 times and the mean value was used for analysis.
Lung function assessment
Lung function tests were performed using 
MasterScreen Pneumo (Erich Jaeger, Germany). 
All tests were done between 7 and 10 A.M. For-
ced expiratory volume in 1 s (FEV1) or maximal 
expiratory flow at 50% of the forced vital capacity 
(MEF50) expressed as percentage of the predicted 
values were used for further analysis. 
Histamine bronchial challenge was perfor-
med as previously described elsewhere [21]. 
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Table 1. Patients characteristics
All (n = 843) AR (n = 422) AA (n = 421) P
Age (years) 27 (22–36) 25 (21–33) 30 (23–40) < 0.001
Height (cm) 172 (164–180) 172 (164–180) 171 (164–180) > 0.05
Weight (kg) 72 (61–81) 70 (60–80) 74 (64–82) < 0.001
BMI 24 (21.6–26.3) 23.4 (21.1–25.8) 24.7 (22.2–27.5) < 0.001
FEV1 (% predicted) 101 (89.8–110.6) 107.5 (100–116) 93.5 (81.9–103) < 0.001
MEF50 (% predicted) 83.5 (63.7–105.4) 100.3 (84.8 – 120) 66.3 (51.96–83) < 0.001
PC20 (mg/ml) 7.2 (1.6–31) 31 (16–64) 1.6 (0.38–3.49) < 0.001
FeNO (ppb) 47.5 (25.8–88) 30.3 (19.2–53.2) 76 (43–121) < 0.001
tIgE (kU/L) 231 (101–432) 146.5 (83–305) 335 (167–551) < 0.001
DpIgE (kU/L) 9.4 (2.2–31.8) 5.04 (1.72–17.3) 17.3 (3.3–44) < 0.001
Sex (% males) 52.6 50.9 54.2 > 0.05
Results are presented as medians with interquartile range.
AA — allergic asthma; AR — allergic rhinitis; BMI — body max index; DpIgE — Dermatophagoides pteronyssinus (Dp) specific IgE; FeNO — fractional exhaled nitric 
oxide; FEV1 — forced expiratory volume in 1 s; MEF50 — maximal expiratory flow at 50% of forced vital capacity; PC20 — histamine provocative concentration causing 
a 20% fall in FEV1; tIgE — total immunoglobulin E
Briefly, all patients inhaled doubling concentra-
tions of histamine starting from a concentration 
of 0.062 mg/mL. Aerosol was generated using 
a DeVilbis No. 646 nebulizer attached to a Ro-
senthal-French dosimeter. All subjects performed 
5 inspiratory capacity breaths of given histamine 
concentration. Forced expiratory maneuvers were 
performed 90 s after each fifth inhalation. The 
procedure was continued until either at least 
a 20% fall of FEV1 or a histamine concentration 
of 32 mg/mL was reached. Bronchial reactivity to 
histamine was expressed as histamine concentra-
tion causing a 20% fall of FEV1 (PC20). In patients, 
in whom the maximal histamine concentration 
produced decrease of FEV1 of more than 10% 
but less than 20% PC20 was calculated by extra-
polation. In patients with negative histamine 
challenge the PC20 concentration of 64 mg/ml was 
used for statistical analysis. 
Immunological assays
The concentration of tIgE and DpIgE were 
evaluated in serum using the Pharmacia CAP 
system (Phadia Diagnostics, Uppsala, Sweden) 
according to the manufacturer instructions.
Statistical analysis
All results are presented as medians with 
95% confidence intervals (95% CI) unless stated 
otherwise. Comparison of individual parameters 
between the studied groups was performed using 
the Mann-Whitney U test. The Shapiro-Wilk test 
was used for evaluation of normal distribution of 
individual parameters. 
Serum concentration of tIgE and DpIgE, PC20, 
and FeNO were logarithmically transformed for 
statistical analysis. The Pearson correlation coeffi-
cient was calculated for evaluation of association 
between two variables. Simple and multiple linear 
regression analyses were used to estimate associa-
tion between AHR and other parameters studied.
Statistical significance was determined at the 
P < 0.05 level.
Results
Patients characteristics is presented in Table 1. 
There was no significant difference of height and 
sex distribution between allergic rhinitis (AR) and 
allergic asthma (AA) patients. Asthmatic patients 
were older and were characterized by greater 
body mass index (BMI), tIgE, DpIgE, FeNO, but 
lower FEV1, maximal expiratory flow at 50% of 
forced vital capacity 50% (MEF50) and PC20 than 
AR patients.
In simple linear regression analysis baseline 
lung function results (reflected as either FEV1 or 
MEF50), logFeNO, logtIgE, logDpIgE, age and BMI affected 
AHR expressed as logPC20 (Table 2). The strongest 
association was demonstrated for FEV1, MEF50 
and logFeNO (r2 = 0.261, 0.350 and 0.274, respecti-
vely). The associations remained significant when 
multiple regression analysis was applied. Using 
multiple regression analysis AHR expressed as 
logPC20 can be best described using the following 
formula: logPC20 = 0.015 × MEF50 - 1.003 × logFeNO – 
0.171 × logDpIgE – 0.114 × BMI + 1.53 (R
2 = 0.548; 
p < 0.001). When the whole group was divided 
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Table 3. Linear regression analysis between logPC20 and the studied parameters in allergic rhinitis (n = 422)
β r2 95% CI P-value
FEV1 0.0004 -0.0022 -0.0021 to 0.0029 > 0.05
MEF50 0.0019 0.0209 0.0007 to 0.0031 < 0.01
LogFeNO -0.2947 0.078 -0.390 to -0.199 < 0.001
LogtIgE -0.0947 0.0122 -0.169 to -0.2 < 0.05
LogDpIgE -0.119 0.045 -0.171 to 0.068 < 0.001
Age -0.0026 0.0022 -0.0064 to -0.0011 > 0.05
BMI -0.0117 0.0122 -0.0209 to -0.0025 < 0.05
Sex 0.0177 -0.0017 -0.0483 to 0.0837 > 0.05
BMI — body max index; FEV1 — forced expiratory volume in 1 s; MEF50 — maximal expiratory flow at 50% of forced vital capacity
Table 2. Linear regression analysis between logPC20 and the individual parameters in the whole group of HDM-APs (n = 843)
β r2 95% CI P-value
FEV1 0.031 0.261 0.027 to 0.034 < 0.001
MEF50 0.018 0.350 0.016 to 0.020 < 0.001
LogFeNO -1.324 0.274 -1.470 to -1.180 < 0.001
LogtIgE -0.70 0.110 -0.56 to -0.31 < 0.001
LogDpIgE -0.460 0.105 -0.55 to -0.367 < 0.001
Age -0.02 0.040 -0.024 to -0.012 < 0.001
BMI -0.045 0.034 -0.061 to -0.030 < 0.001
Sex 0.115 0.002 -0.013 to 0.243 > 0.05
Asthma -1.489 0.616 -1.570 to -1.409 < 0.001
BMI — body max index; FEV1 — forced expiratory volume in 1 s; HDM-APs — house dust mite allergic patients; MEF50 — maximal expiratory flow at 50% of forced 
vital capacity
according to the clinical asthma diagnosis FeNO 
and DpIgE demonstrated the strongest association 
with AHR in both AR and AA, while lung function 
expressed as FEV1 or MEF50 demonstrated strong 
association in AA but in AR only MEF50 (p < 0.01) 
but not FEV1 (p > 0.05) was associated with AHR 
(Table 3 and 4). 
To address a  possible interactions of age 
and BMI correlation between those factors and 
functional and immunological parameters was 
performed. In HDM-AA lung function parameters 
MEF50 (r = -0,3178; 95%CI -0,3772 to -0,2557; p 
< 0,0001) and FEV1 (r = -0,1405; 95% CI -0,2060 
to -0,0736; p < 0,0001) correlated with age (Fi-
gure 1). Similarly significant correlation between 
age and logDpIgE (r = -0,1349; 95% CI -0,2006 to 
-0,0680; p = 0,0001) could be demonstrated (Figu-
re 1). Neither logFeNO (r = 0,0474; 95% CI -0,0202 
to 0,1145; p>0.05) nor logtIgE (r = 0,0232; 95% CI 
-0,0444 to 0,0906; p>0.05) correlated with age 
(not shown). Similarly lung function parameters 
including MEF50 (r = -0,2475; 95% CI -0,3099 to 
-0,1830; p < 0.0001) and FEV1 (r = -0,1477; 95% 
CI -0,2131 to -0,0810; p < 0.0001) correlated 
inversely with BMI (Figure 1). However neither 
logFeNO (r = 0,0526; 95% CI -0,0149 to 0,1197; 
p>0.05) (Figure 1) nor logDpIgE (r = -0,0299; 95% CI 
-0,0972 to 0,0377; p>0.05) nor logtIgE (r = 0,0595; 
95% CI -0,0080 to 0,1266; p>0.05) correlated with 
BMI (not shown). 
Discussion
Our study evaluated predictors of AHR 
among several functional and immunological pa-
rameters frequently assessed in allergic patients. 
In this study we demonstrated that baseline lung 
function expressed as MEF50 in combination with 
a marker of airway inflammation FeNO are two 
main independent predictors of AHR in HDM
-allergic patients. The presented results seem to 
indirectly support the concept of the pathogenesis 
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Table 4. Linear regression analysis between logPC20 and the studied parameters in allergic asthma (n = 421)
β r2 95% CI P-value
FEV1 0.017 0.106 0.013 to 0.022 < 0.001
MEF50 0.013 0.164 0.01 to 0.016 < 0.001
LogFeNO -0.748 0.109 - 0.952 to 0.545 < 0.001
LogtIgE -0.375 0.041 -0.546 to -0.205 < 0.001
LogDpIgE -0.245 0.046 -0.349 to -0.141 < 0.001
Age -0.035 0.0006 -0.01 to -0.003 > 0.05
BMI -0.0113 0.0015 -0.029 to -0.006 > 0.05
Sex 0.114 0.0032 -0.032 to 0.259 > 0.05
Age (years) Age (years) Age (years)
BMI (kg/m2) BMI (kg/m2) BMI (kg/m2)
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Figure 1. Correlation of age (A–C) and BMI (D–F) with FEV1 (A, D), MEF50 (B, E) and logDpIgE in house dust mite allergic patients
of AHR in which airway remodeling and airway 
inflammation play major additive roles. Assess-
ment of FeNO was used as a  surrogate marker 
of eosinophilic inflammation in the airways. It 
allows for relatively simple and noninvasive 
evaluation of intensity of airway inflammation 
and therefore is useful in large, epidemiological 
studies. It has already been demonstrated that 
the number of eosinophils in induced sputum 
strongly correlates with logFeNO [22]. Moreover, 
the intensity of airway eosinophilic inflammation 
either demonstrated as number of eosinophils in 
induced sputum or FeNO correlates with AHR 
particularly in patients with relatively short 
duration of asthma [22]. However, in asthmatic 
patients with longer duration of the disease 
structural changes in the airways seem to be 
more important determinants of AHR [22]. This 
is consistent with our study since the selected 
patients were mostly young adults and therefore 
significant association of FeNO with AHR could 
be demonstrated [22]. Airway inflammation 
triggered by allergen exposure is reflected by in-
crease in FeNO [21, 22]. Interestingly FeNO was 
associated with AHR in the whole HDM-allergic 
population and also in both subgroups of ARs 
and AAs. Moreover, FeNO did not correlate with 
age which indicates that airway inflammation is 
related to AHR independently of the duration of 
this process. On the other hand, lung function 
in particular MEF50 or FEV1 was significantly 
correlated with age indicating that impaired 
lung function develops with the progression of 
the disease or possibly with duration of allergen 
A B C
D E F
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exposure. This is consistent with a study which 
evaluated longitudinally over a period of 10 years 
the prevalence of atopy and AHR in 8-10 years 
old children [23]. The study demonstrated that 
atopy is a risk factor not only for current presence 
but also for future development of AHR. In fact, 
allergic rhinitis is a  risk factor for developing 
asthma and AHR [24]. Greater risk for developing 
asthma in ARs was demonstrated in both children 
and adults [24]. In some populations as many 
as 50% of ARs not treated with allergen immu-
notherapy developed asthmatic symptoms over 
time [24]. In our study the association of baseline 
lung function expressed as FEV1 with AHR was 
seen only in AAs but not in ARs. This indicates 
that in a subgroup of ARs baseline lung function 
parameters are less important determinants of 
AHR than in AA patients. One may speculate that 
the effect may partially depend on the duration 
of allergic process as patients with asthma were 
older than rhinitis patient. However, significant 
association of MEF50 with AHR seen in both sub-
groups indicate that involvement of distal airways 
may be important in both ARs and AAs. This is 
further supported by correlation of MEF50 with 
age in both ARs and AAs. Our study indicates 
that airway structural changes and inflammation 
play an important role in the pathogenesis of AHR 
as demonstrated by independent association of 
MEF50 and FeNO with AHR. 
In lane with our results is a study which sho-
wed in a large group of allergic rhinitis patients 
that forced expiratory flow 25–75% (FEF25–75) 
was a predictor of AHR [25]. This is consistent 
with our observations which demonstrate in ARs 
a significant association of AHR with MEF50 but 
not FEV1. 
In addition our study shows that allergen spe-
cific IgE is an independent risk factor for AHR in 
house dust mite allergic patients and its effect is 
significant both in AA and AR patients. Moreover, 
in AR patients allergen specific IgE concentration 
is a major factor determining AHR. Atopy has 
been recognized as a risk factor for asthma and the 
intensity of atopy correlates with risk of asthma 
[26]. Sensitization to individual allergens impo-
ses different risk for developing AHR [10–13]. 
Patients sensitized to perennial allergens have 
greater risk for developing AHR and asthma than 
those sensitized to seasonal allergens [10–13]. In 
order to avoid those confounding factors we eva-
luated a homogenous group of patients allergic to 
HDM. House dust mite allergy is a major risk fac-
tor for asthma development among children and 
young adults [12]. Our study is consistent with 
the above mentioned publications indicating that 
IgE-mediated effects affect AHR in an independent 
of eosinophilic airway inflammation way. It is 
tempting to speculate that our analysis support the 
concept of interference with IgE as a therapeutic 
strategy which should affects AHR. Moreover, it 
may explain why in allergic asthmatics allergen 
immunotherapy or omalizumab may have syner-
gistic effect with therapeutic options interfering 
with eosinophilic inflammation such as inhaled 
corticosteroids. In addition our study indicates 
that at different stages of allergic diseases different 
components play a dominant role in development 
of AHR. A recently published experimental study 
seems to support this concept demonstrating IgE 
independent effect of HDM on development of 
airway inflammation and AHR [26]. 
Finally, in our population BMI was also in-
dependently associated with AHR. Association of 
BMI with AHR has been demonstrated in some 
but not all studies [27–28]. The effect of BMI on 
the development of asthma may depend on the 
age of occurrence of the disease, being significant 
in young children but not in adults [29]. This 
however, supports the direct rather than indirect 
effect of obesity on asthma development. An 
experimental asthma model provided evidence 
that independent risk factors obesity and allergy 
to HDM synergized in development of asthma 
phenotype resistant to corticosteroids [30]. 
In summary our study demonstrates that even 
in a well-characterized population of HDM-aller-
gic patients lung function parameters, FeNO and 
DpIgE are major, independent predictors of AHR 
indicating targets for therapeutic intervention and 
emphasizes possible synergistic effect of anti-IgE 
and anti-eosinophilic therapy. 
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